Linaclotide

利那洛肽

Report date: 2026/05/08 20:02:52
NMEFirst In Class

Base Information

Drug NameLinaclotide
Drug Alias NameLinaclotide acetatelinaclotidumlinaclotidelinaclotidaConstella +[13] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionNatriuretic peptide receptor 3 agonists
TargetsNatriuretic peptide receptor 3
Therapy Area/IndicationsChronic idiopathic constipationBreast FeedingOpioid-Induced Constipation +[7] 
Global Approved IndicationsChronic idiopathic constipationConstipationIrritable Bowel Syndrome
Approved Indications in ChinaIrritable Bowel Syndrome
Original Approved Country/TerritoryUnited States
Original Approved Date2012/08/30
Country/TerritoryBelgiumBulgariaCanada +[22] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesIronwood Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of NottinghamAstellas Pharma IncAbbvie Inc +[6] 
Inactive CompaniesAllergan PlcAstrazeneca PlcNational Cancer Institute +[6] 
Active IndicationsChronic idiopathic constipationConstipationCystic Fibrosis +[4] 
Inactive IndicationsBreast FeedingOpioid-Induced ConstipationColorectal Neoplasms

Other Information

ATC CodeA06AX04
Related LinksWikipediaDrugBankKEGG